Nuvation Bio Inc [NUVB] stock prices are down -0.29% to $6.99 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NUVB shares have gain 43.83% over the last week, with a monthly amount glided 59.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on November 19, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $12. Previously, Jefferies started tracking the stock with Buy rating on September 30, 2025, and set its price target to $10. On April 23, 2025, Citizens JMP initiated with a Mkt Outperform rating and assigned a price target of $6 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $10 on March 27, 2024. BTIG Research upgraded its rating to a Buy but $5 remained the price target by the analyst firm on March 26, 2024. Jefferies downgraded its rating to Hold for this stock on January 06, 2023, and downed its price target to $2. In a note dated August 02, 2022, BTIG Research downgraded a Neutral rating on this stock.
The stock price of Nuvation Bio Inc [NUVB] has been fluctuating between $1.54 and $7.50 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $6.99 at the most recent close of the market. An investor can expect a potential return of 43.06% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
The Nuvation Bio Inc [NYSE:NUVB] reported sales of 26.75M for trailing twelve months, representing a surge of 1704.68%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -8.71%, Pretax Profit Margin comes in at -8.13%, and Net Profit Margin reading is -8.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.55 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.62 points at the first support level, and at 6.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.25, and for the 2nd resistance point, it is at 7.51.
Ratios To Look Out For
It’s worth pointing out that Nuvation Bio Inc [NYSE:NUVB]’s Current Ratio is 8.48. Also, the Quick Ratio is 8.39, while the Cash Ratio stands at 1.45. Considering the valuation of this stock, the price to sales ratio is 89.85, the price to book ratio is 7.35.
Transactions by insiders
Recent insider trading involved Hanley David C., CHIEF TECHNICAL OPERATIONS, that happened on Nov 19 ’25 when 0.2 million shares were sold. Officer, GARY HATTERSLEY completed a deal on Nov 20 ’25 to buy 0.37 million shares. Meanwhile, Officer DONGFANG LIU bought 20000.0 shares on Nov 20 ’25.
